Medtronic, Inc. (MDT): Is This Stock in Your Portfolio? If Not, Then Consider Getting Some

Page 1 of 2

The market gives investors a good number of chances to buy stocks when they are beaten down, and one such opportunity presented itself when medical devices maker Medtronic, Inc. (NYSE:MDT) slipped in February this year. There were concerns about the company’s business slowing down, but its fourth-quarter results, which were released in May, put such doubts to rest.

Medtronic’s huge size and diversification have helped the company overcome challenges, so it is not surprising that shares have continued their steady appreciation so far this year, rising almost 30%. And once you consider the company’s prospects, it won’t be surprising if the stock continues to fly higher.

An important turnaround

Medtronic, Inc. (NYSE:MDT)

For starters, Medtronic, Inc. (NYSE:MDT)’s implantable cardioverter defibrillators (ICD) and pacemakers, which were the primary reason behind the bearishness of analysts on the stock, are back on the growth path. Sales of defibrillators grew 2% in the previous quarter while pacemaker revenue improved 5% (both excluding currency effects) from the year-ago period.

These improvements are really significant, as both these products were struggling but now seem to be growing again as Medtronic, Inc. (NYSE:MDT) gained market share, and more importantly, helped revenue from its Cardiac Rhythm Disease Management (CRDM) business grow 4% (excluding currency effects). This should have come as welcome relief to Medtronic investors as CRDM has struggled of late.

This market share gain in the CRDM doesn’t come as a surprise as Medtronic, Inc. (NYSE:MDT) was well-positioned to gain from the deficiencies in the ICD offering of its competitor, St. Jude Medical, Inc. (NYSE:STJ). St. Jude’s ICD, the Riata, has faced difficult times and was the subject of a recall in late 2011. The leads inside the defibrillator could break out of the insulation from the inside, according to The Wall Street Journal, and this should have played a part in Medtronic’s share gain.

Now, Medtronic, Inc. (NYSE:MDT) is looking to maintain its new-found momentum in ICD by launching new and improved devices, such as the Evera ICD. Evera would be of smaller size, and the company has made an effort to increase patient comfort through it. Such moves should help Medtronic keep its market share intact in this segment.

Growth ahead

Next, Medtronic has been aggressively focusing on emerging markets to drive international growth. The company’s international revenue has grown consistently in a range of 6%-8% for almost three years, and emerging markets have been the primary drivers of this growth. Going forward, the company is confident of keeping its momentum intact as it increases its presence and builds awareness.

Moreover, Medtronic, Inc. (NYSE:MDT) has been making some notable moves of late as far as new products are concerned. Its advanced insulin pump, which can automate delivery of insulin for Type 1 diabetics through a “threshold suspend” feature is being touted as a breakthrough technology. The company has filed for FDA approval of the device and if approved, it would be a big boost for it.

Also, Medtronic recently received the CE mark for its CoreValve device in Europe, which should improve its standing in the competitive heart valve market in Europe. In addition, its Pacific Plus PTA catheter also received the go-ahead from the FDA along with the European CE mark. These product moves should complement Medtronic’s global presence and help its revenue grow going forward.

Risks to consider

However, being a medical devices manufacturer, Medtronic, Inc. (NYSE:MDT) isn’t immune to the perils of the industry. For instance, the company’s spine business has been a mixed performer and a recent revelation that its Infuse bone graft product, which accelerates bone growth after spinal surgery, doesn’t enjoy an advantage over traditional bone graft procedures led to a dip in share price and might lead to a decline in sales of the product.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!